CMS wants faster drug prior authorization. What would change for patients?

If you are hoping this new CMS proposal will quickly fix prescription-drug prior authorization, the plain answer is no. CMS released the proposal on April 10, 2026, and it was published in the Federal Register on April 14, 2026, but it is still only a proposed rule. For most patients, the biggest changes would not begin until October 1, 2027 if CMS finalizes it.

That timing matters because some readers may already be seeing new prior-authorization data posted online in 2026 under an older CMS rule. Those March 31, 2026 postings are for non-drug items and services, such as scans, equipment, and procedures. They do not cover prescription-drug prior authorization.

What happened, and why now?

CMS says the new proposal is meant to extend many of its newer interoperability and prior-authorization rules from non-drug care to drugs. In practice, that means trying to move more of the process into standardized electronic systems instead of relying so heavily on phone calls, faxes, and payer-specific portals. Public comments are open for 60 days after publication in the Federal Register, so this is still a policy in progress, not a final guarantee.

What the proposal would actually do

The core change is electronic prior authorization for drugs in programs CMS oversees. For drugs covered under a medical benefit, CMS proposes requiring affected payers to build drug-related coverage and documentation requirements into the same prior-authorization API framework already used for many non-drug items and services. For some Medicaid, CHIP, and federally facilitated exchange plans, CMS also proposes electronic prior authorization standards for certain drugs covered under a pharmacy benefit.

The goal is practical rather than flashy: let clinicians check coverage rules, submit requests, and receive decisions in a more consistent electronic workflow. That could reduce some administrative friction. But it would not end prior authorization, and it would not mean every request gets approved.

Which plans are covered, and which are not?

This proposal does not apply to every insurer in the United States. CMS says the main groups in scope are Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the federally facilitated exchanges. CMS also proposes adding small-group market issuers on the federally facilitated SHOP exchanges.

That still leaves out many employer-sponsored plans, many off-exchange commercial plans, and other private coverage arrangements. So even if the rule is finalized, its effect would depend on what kind of coverage a patient actually has.

What already changed in 2026 under the older rule

The 2024 CMS final rule already set several prior-authorization requirements in motion for non-drug items and services. Starting in 2026, affected payers must provide specific reasons for denied prior-authorization decisions for those non-drug requests, and they must publicly post annual prior-authorization metrics. Those website postings can help patients compare broad approval, denial, appeal, and response-time patterns. But the older rule explicitly excluded prescription-drug prior authorization.

What would start in October 2027 if the rule is finalized

October 1, 2027 is the key date to watch. If the proposal is finalized largely as written, that is when many of the drug-related electronic prior-authorization requirements would begin. CMS also proposes some drug-decision timing rules starting then, but the exact deadlines would vary by program.

For Medicaid and CHIP, CMS proposes decision timeframes that align with existing short statutory or regulatory clocks, depending on the type of drug request. For Qualified Health Plan issuers on the federally facilitated exchanges, CMS proposes notice to the requesting provider within 72 hours for standard drug prior-authorization requests and 24 hours for expedited requests. CMS also proposes requiring specific denial reasons for drug prior-authorization requests in Medicaid, CHIP, and federally facilitated exchange plans in scope.

That is an important limitation: patients should not assume every covered program would follow the exact same denial-notice or turnaround rules, and they should not assume the proposal reaches all commercial drug coverage.

What would come later in 2028

One of the most useful patient-facing changes would arrive later. CMS proposes public reporting of drug prior-authorization metrics beginning in 2028 using data from the 2027 reporting period. That could finally give patients and families a more comparable view of how often drug prior authorizations are approved, denied, reversed on appeal, or delayed.

Even there, the details vary. For Medicare Advantage, the proposed public reporting would cover drugs payable under Part B, not Medicare Part D drugs. For Medicaid, CHIP, and the federally facilitated exchange plans in scope, the reports would cover drugs subject to prior authorization under those programs’ benefit rules.

Why this matters even though it is not immediate relief

Prior authorization is not a small issue. KFF reports that Medicare Advantage insurers made 52.8 million prior-authorization determinations in 2024 and denied 4.1 million of them, or 7.7%. Only 11.5% of denied requests were appealed, but 80.7% of appealed denials were partially or fully overturned. Those figures do not prove every initial denial was inappropriate, but they do show why patients often experience prior authorization as delay as much as denial.

A recent peer-reviewed cross-sectional study published in JAMA Health Forum and indexed in PubMed found similar friction on the prescription side. The study examined 205,896 branded medication dispensations in the United States that initially hit prior-authorization rejections. Only 35% were processed the same day, and 54% were eventually approved. That study adds useful context, but it also has limits: it focused on branded retail pharmacy claims, not all drugs or all insurance situations, and it cannot tell readers whether any individual denial was clinically appropriate.

What readers can do now

If you are dealing with a prescription delay today, this proposal does not change your coverage rules yet. A practical next step is to ask your plan, pharmacy, or prescribing clinician whether the review is happening under the medical benefit or the pharmacy benefit, what exact reason was given for any delay or denial, whether expedited review is available, and what the appeal deadline is. Keep copies of messages, denial letters, and dates.

Do not stop or change a medication on your own because of an insurance delay. If the drug is urgent or your condition is getting worse, contact the prescribing clinician promptly. Seek urgent or emergency care for severe, rapidly worsening, or dangerous symptoms.

The bottom line: CMS is proposing a meaningful expansion of prior-authorization rules to prescription drugs, but it is not immediate relief for most people in 2026. The main value right now is understanding the timeline: some transparency rules for non-drug care are already live, many drug-related electronic requirements would not start until October 2027 if finalized, and broader public reporting on drug prior authorization would generally not appear until 2028.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.